11/03/2026 | Press release | Distributed by Public on 11/03/2026 16:07
Reflections from the 2026 Veeva R&D Summit
Sweta Pittala
Vice President, Technology Portfolio, IT R&D
AI is advancing rapidly across clinical research, but moving from promising demonstrations to sustainable, real-world impact remains a significant challenge.
At the 2026 Veeva R&D Summit, Chief Operations Officer Nicholas Spittal and I shared Velocity Clinical Research's experience putting AI into production, including the lessons we've learned along the way. What made the discussion especially interesting was hearing where other organizations are in their own AI journeys.
We opened by asking the audience: Where is your organization today with AI in clinical operations? The responses offered a revealing snapshot:
This was an informal poll, but the message was clear: AI enthusiasm is widespread, yet scaling beyond pilots is still a work in progress.
We then asked a second question: What makes AI hardest to operationalize? The word cloud was telling. Trust, security, cost, legal considerations, hallucinations, and training stood out, alongside validation, alignment, and other operational concerns. Notably, these challenges aren't mainly about what AI models can do. They're about what organizations need to build around AI to make it work reliably.
We've deployed 26 AI agents across our operational workflows, and the experience has reinforced an important distinction: automating a task is not the same as transforming a business process.
To illustrate, we shared our accounts receivable operations (AROps) implementation. The goal was to prevent revenue leakage, improve invoicing, and strengthen cash collection by connecting contractual terms, operational activities, billing triggers, and payment reconciliation. On paper, the process looked straightforward. In practice, it meant navigating inconsistent contract formats, connecting information across systems, interpreting operational triggers, and handling exceptions.
Several lessons emerged that reach well beyond AROps:
The audience discussion reinforced what we've experienced firsthand: scaling AI is as much an operational and organizational challenge as a technology one. Real progress will take collaboration across research sites, sponsors, CROs, and technology partners to reduce unnecessary variation, improve interoperability, and design workflows that work for both people and technology.
At Velocity, our ambition isn't simply to deploy more AI agents. It's to create connected, intelligent workflows that improve operational performance while giving our teams more time for patients, quality, and higher-value decisions.
Ultimately, the measure of AI success isn't how impressive the technology looks in a demo. It's how reliably it delivers value in everyday operations. AI can only scale as well as the people, processes, and ecosystem around it.
Thank you to everyone who joined our session at the Veeva R&D Summit and contributed to the conversation. It was encouraging to see such a shared focus on moving beyond experimentation toward practical, responsible AI adoption.